BCL2L1 and ovarian cancer: Moreover, we showed that co-inhibition of NF-κB and STAT5 pathways, either by specific shRNAs or small molecule inhibitors, synergistically reduced the chemoresistance potential in carboplatin-resistant ovarian cancer cells partly through suppression of Bcl-xL expression.